文献速递临床试验与 GCP基础与转化研究

玻璃体内光开关疗法治疗晚期视网膜色素变性:一项1期开放标签试验

Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial.
PubMed 文献 · Nat Med · 2026-04-14

这项首次人体、1期、基因无关、开放标签、剂量递增试验在6名晚期视网膜色素变性患者的12只眼中评估了玻璃体内注射KIO-301的安全性。主要30天安全性终点达标,无严重不良事件或剂量限制性毒性,探索性评估显示部分参与者光感知和功能视觉有变化。

要点

  • 玻璃体内KIO-301在晚期RP中总体安全耐受,无严重不良事件或剂量限制性毒性。
  • 所有眼部不良事件均为轻度且与操作相关,无药物相关眼内炎症。
  • 探索性指标提示部分参与者光感知、功能视觉及皮层BOLD信号出现变化。

核心结论

  • 在晚期视网膜色素变性患者中,玻璃体内KIO-301显示出可接受的安全性和耐受性,支持光开关疗法的可行性并值得在更大规模试验中进一步评估。

研究设计与样本

  • 首次人体、1期、基因无关、开放标签、剂量递增临床试验,KIO-301经玻璃体内注射给予6名参与者的12只眼,主要终点为30天眼部和全身安全性。

主要发现

  • 主要安全性终点达标,任何时间点均未观察到严重不良事件或剂量限制性毒性。
  • 未发生药物相关眼内炎症,所有眼部不良事件均为轻度且与操作相关。
  • 探索性评估发现部分参与者的光感知和功能视觉指标存在差异。
  • 给药后视觉皮层区域观察到光诱发的血氧水平依赖信号变化,其时间模式与药效学活性相符。
  • 参与者报告的生活质量评分随时间变化。

局限性

  • 这是一项小样本、非随机的1期研究,受试者为晚期视网膜色素变性患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A small azobenzene photoswitch molecule (KIO-301), designed to confer light responsiveness to retinal ganglion cells, was evaluated for safety and feasibility in a first-in-human, phase 1, gene-agnostic, open-label, dose-escalation clinical trial in individuals with advanced retinitis pigmentosa (RP). KIO-301 was administered by intravitreal injection to 12 eyes of 6 participants. The primary outcome was ocular and systemic safety over 30 days. Secondary and exploratory assessments included functional vision testing, visual acuity, kinetic visual field, functional magnetic resonance imaging and participant-reported outcomes. The primary safety outcome was met, with no serious adverse events or dose-limiting toxicities observed at any point. No drug-related intraocular inflammation occurred, and all ocular adverse events were mild and procedure-related. Exploratory assessments identified variation in light perception and functional vision measures in some participants. Light-evoked blood-oxygen-level-dependent signal changes in visual cortical regions were observed following dosing and showed a temporal pattern compatible with pharmacodynamic activity. Participant-reported quality-of-life scores varied over time. In this small, nonrandomized phase 1 study in individuals with late-stage RP, intravitreal KIO-301 demonstrated an acceptable safety and tolerability profile, supporting the feasibility of photoswitch therapy in advanced RP, and motivating further evaluation in larger trials. ClinicalTrials.gov identifier: NCT05282953.

来源:Nat Med,查看原文。版权归原作者所有。

引用

  1. Casson RJ, Daniels E, Barras CD, et al. Intravitreal photoswitch therapy in advanced retinitis pigmentosa: a phase 1 open-label trial. Nat Med. 2026. PMID: 41981307. doi:10.1038/s41591-026-04317-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。